Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS.

In this episode, we discuss:

• Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuro
• How brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs across the BBB
• How new modalities that reach the brain can potentially treat diseases like Alzheimer’s, Parkinson’s, ALS, and lysosomal disorders
• Why delivery route of shuttles enable IV or subcutaneous dosing instead of invasive intrathecal injections
• How early data shows that shuttle-enabled antibodies clear amyloid faster, at lower doses, and with fewer side effects
• How the field is accelerating through a pre-competitive consortium model that lets multiple companies share shuttle platforms

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank